Ulf Nehrbass

CEO
Luxembourg Institute of Health

Ulf Nehrbass serves as CEO of LIH, the Luxembourg Institute of Health. The institute is focusing on biomedical and translational research with the aim of impacting on patients.

Ulf Nehrbass has spent his career focusing on the application of excellent research towards unmet patient needs. As the Director and founder of Institut Pasteur Korea he established one of the first translational drug discovery institutes. The project, starting in 2004, relied on target-free, visual drug discovery with live disease models. This resulted in the development of Q203, a first in class compound and the world’s most potent candidate against tuberculosis, currently in Clinical Phase II. Ulf Nehrbass was also founder and CEO of Qurient Therapeutics, which has undergone a successful I.P.O. in 2016. More recently Ulf started the French German translational center, Ksilink, which was co-founded by Sanofi, INSERM, the Helmholtz Gemeinschaft and others. Based in Strasbourg, France, Ksilink is employing Artificial intelligence approaches to enable patient-based drug discovery. Founded in 2014 Ksilink is becoming a highly successful player in this emerging field.

Prior to his translational engagement Ulf worked as a Chef d’Unité at the Institut Pasteur in Paris and a research associate with the Howard Hughes Medical Institute at the Rockefeller University in New York. He did his studies in Biochemistry at Cambridge University, UK and performed his thesis work with a PhD fellowship at EMBL in Heidelberg. In 2006, Ulf Nehrbass was nominated EMBO fellow.